Crescent Biopharma, Inc. (CBIO) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 5:35 PM EDT
Company Participants
Joshua Brumm – CEO & Director
Ellie Im – Chief Medical Officer
Jonathan McNeill – President & COO
Conference Call Participants
Robert Klingenberger
Presentation
Robert Klingenberger
Well, great. Good evening. My name’s Bob Klingenberger. I’m an Executive Director with Morgan Stanley. Thrilled to be here with the Crescent team. For any information regarding research disclaimers, please go to www.morganstanley.com/researchdisclaimers. And if any questions, feel free to ask your Morgan Stanley representative.
And thrilled, like I said, to be joined by the Crescent team. And I’ll turn it maybe to Josh Brumm, Chief Executive Officer, to give a brief kind of introduction about the company and what you all have upcoming. And then we’ll dive into some questions.
Joshua Brumm
CEO & Director
Great, and thank you for inviting us, Bob. It’s great to be here. Our own disclaimers, we have to start with the forward-looking statements. So, if you have any questions on that, please see our SEC filings. Again, great to be here. We’ve got a lot of exciting things coming up for Crescent in the second half of this year, really heading into a wealth of data coming starting in Q1 ’27.
For those of you who may not know, we started this company with the view that synergistic combinations in oncology is the way of the future. That’s where the space is moving. We have a two-pronged approach to deliver on that thesis. First is we have a PD-1/VEGF bispecific, CR-001. That’s clinical-stage molecules in development now. And we’re very excited about that being a potential next backbone for IO therapy in oncology.
And then the other sleeve of our business and that strategy is, we have built our